Combination of potential biomarkers may help predict response to immunotherapy in kidney cancer

Currently, it is difficult for clinicians to decide which patients will respond to immunotherapy and, therefore, what is the best course of treatment for patients with metastatic renal cell carcinoma (RCC). A recent study published in Oncoimmunology describes a combination of two potential biomarkers that may help predict response to immunotherapy for metastatic RCC patients, […]

read more

The future of immunotherapy-based combinations for metastatic kidney cancer

The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]

read more

Combination PD-1 and PD-L1 inhibitors for kidney cancer are no more beneficial than PD-1 inhibitor alone

A recent phase II clinical trial has shown that combined use of a PD-1 inhibitor and a PD-L1 inhibitor proved no more beneficial than anti-PD-1 treatment alone in metastatic renal cell carcinoma (RCC) patients who had already been treated with targeted therapy. There was no significant difference in the primary endpoint of the study, which […]

read more

PD-L1 can be used to predict the likely course of kidney cancer

A recently published study evaluated the role of programmed-death receptor ligand (PD-L1) as an indicator of the likely course (prognosis) of clear cell renal cell carcinoma (RCC). A total of 738 patients were included in the study and followed for around 34 months. The presence of PD-L1 and PD-1 receptors in the tumour cells was […]

read more

PD-L1 expression and clinical outcomes with targeted therapy

A recent study published in Clinical Cancer Research analysed tumour tissue samples obtained in a clinical trial to investigate how the expression of the PD-L1 receptor on the tumour cells influenced outcomes in patients with metastatic renal cell carcinoma (RCC) receiving targeted therapy. Positive expression of the PD-L1 receptor on RCC tumour cells was associated […]

read more

Immune checkpoint inhibitors are more effective in PD-L1 positive patients

Immune checkpoint inhibitors, such as nivolumab, ipilimumab or pembrolizumab are often used alone or in combination with other drugs for the treatment of metastatic renal cell carcinoma (RCC). Unfortunately, researchers are yet to identify a reliable biomarker to predict a patient’s response to immune checkpoint inhibitors. PD-L1 is a potential biomarker for the effectiveness of […]

read more

ASCO 2019: Biomarkers for advanced renal cell carcinoma from the JAVELIN Renal 101 study

Results from the biomarker analysis from the JAVALIN Renal 101 clinical trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago this week. JAVELIN Renal 101 compared the avelumab plus axitinib combination with sunitinib. There were 886 patients in the study, 442 received the combination and 444 received sunitinib. For […]

read more

Atezolizumab plus bevacizumab combination for untreated metastatic kidney cancer

Results from this phase III trial of atezolizumab plus bevacizumab versus sunitinib for patients with untreated renal cell carcinoma (IMmotion 151) were published in The Lancet last month. The study involved 915 patients, of which 40% were positive for PD-L1 biomarkers. In the PD-L1 positive group of patients, the combination of atezolizumab plus bevacizumab was […]

read more

Avelumab plus axitinib granted FDA approval for advanced kidney cancer

The Food and Drug Administration (FDA) in the United States has approved the avelumab (Bavencio) plus axitinib (Inlyta) combination for first-line treatment of advanced renal cell carcinoma (RCC). The approval is the first by the FDA for an anti-PD-L1 therapy as part of a combination treatment for patients with advanced RCC. Around 20-30% of people […]

read more

PD-1, PD-L1 and PD-L2 levels differ between patients

In a recent study, published in BMC Cancer last month, it was reported that the levels of the programmed cell death proteins PD-1, PD-L1 and PD-L2 varied between primary tumour, metastases and site of metastases. For example, PD-L1 was higher in metastatic tumours compared with primary tumours, and PD-1 expression was 65.3% in lung/lymph metastases […]

read more
Showing 1 to 10 of 12 results
  TOP